<p>Leerink Partners 分析师 Jeffrey La Rosa 维持了对 SNTI 股票的看涨态度，并在 12 月 10 日给予了买入评级。</p>
<h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Jeffrey La Rosa 给予买入评级的原因是多种因素的结合，突显了 Senti Biosciences 的主要疗法 SENTI-202 在治疗复发或难治性急性髓性白血病（r/r AML）方面的良好潜力。最近的 SENTI-202 第一期更新显示出令人鼓舞的结果，特别是在疗效和安全性方面，La Rosa 认为这降低了对该项目进一步投资的风险。尽管样本量较小，但该疗法显示出有利的疗效信号，整体生存率的强指标包括高比例的 MRD 阴性和竞争性的反应持续时间。</p>
<p>此外，SENTI-202 的积极安全性特征表现为轻微的急性免疫相关毒性和快速的造血干细胞恢复，进一步支持其相较于现有治疗方案的潜在优势。该疗法独特的逻辑门 CAR 和 NK 细胞底盘有助于其差异化的安全性和疗效，可能允许更广泛的患者适应性。然而，La Rosa 指出，Senti Biosciences 的主要风险在于财务，考虑到他们当前的现金状况，这突显了确保额外资金以推进该项目的重要性。</p>
<p>在 12 月 10 日发布的另一份报告中，H.C. Wainwright 也维持了对该股票的买入评级，目标价为 12.00 美元。</p>

<p>SENTI-202 在急性髓性白血病治疗中的良好潜力：尽管存在财务风险，仍建议买入</p>

<p>Leerink Partners analyst Jeffrey La Rosa has maintained their bullish stance on SNTI stock, giving a Buy rating on December 10.</p>
<div class="lb-trans"><p>Leerink Partners 分析师 Jeffrey La Rosa 维持了对 SNTI 股票的看涨态度，并在 12 月 10 日给予了买入评级。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Jeffrey La Rosa has given his Buy rating due to a combination of factors that highlight the promising potential of Senti Biosciences’ lead therapy, SENTI-202, in treating relapsed or refractory acute myeloid leukemia (r/r AML). The recent Phase 1 update for SENTI-202 demonstrated encouraging results, particularly in terms of efficacy and safety, which La Rosa believes de-risk further investment in the program. Despite the small sample size, the therapy showed a favorable emerging efficacy signal with strong indicators of overall survival, such as high rates of MRD-negativity and competitive duration-of-response.</p>
<div class="lb-trans"><p>Jeffrey La Rosa 给予买入评级的原因是多种因素的结合，突显了 Senti Biosciences 的主要疗法 SENTI-202 在治疗复发或难治性急性髓性白血病（r/r AML）方面的良好潜力。最近的 SENTI-202 第一期更新显示出令人鼓舞的结果，特别是在疗效和安全性方面，La Rosa 认为这降低了对该项目进一步投资的风险。尽管样本量较小，但该疗法显示出有利的疗效信号，整体生存率的强指标包括高比例的 MRD 阴性和竞争性的反应持续时间。</p>
</div><p>Additionally, SENTI-202’s positive safety profile, characterized by mild acute immune-related toxicities and rapid hematopoietic stem cell recovery, further supports its potential advantage over existing treatment options. The therapy’s unique logic-gate-CARs and NK cell chassis contribute to its differentiated safety and efficacy, potentially allowing for broader patient eligibility. However, La Rosa notes that the primary risk for Senti Biosciences is financial, given their current cash position, which underscores the importance of securing additional funding to advance the program.</p>
<div class="lb-trans"><p>此外，SENTI-202 的积极安全性特征表现为轻微的急性免疫相关毒性和快速的造血干细胞恢复，进一步支持其相较于现有治疗方案的潜在优势。该疗法独特的逻辑门 CAR 和 NK 细胞底盘有助于其差异化的安全性和疗效，可能允许更广泛的患者适应性。然而，La Rosa 指出，Senti Biosciences 的主要风险在于财务，考虑到他们当前的现金状况，这突显了确保额外资金以推进该项目的重要性。</p>
</div><p>In another report released on December 10, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.</p>
<div class="lb-trans"><p>在 12 月 10 日发布的另一份报告中，H.C. Wainwright 也维持了对该股票的买入评级，目标价为 12.00 美元。</p>
</div>

SENTI-202 在治疗急性髓性白血病方面展现出良好的潜力：尽管存在财务风险，仍建议买入